GS 9688Alternative Names: GS-9688
Latest Information Update: 21 Dec 2016
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 06 Dec 2016 Preclinical trials in Hepatitis B in New Zealand (PO) (ACTRN12616001646437p) before October 2016
- 06 Dec 2016 Gilead Sciences plans a phase I trial for Hepatitis B (In volunteers) in New Zealand (ACTRN12616001646437p)